New memory drug moves into Phase 1 clinical study

January 1, 2016

An experimental drug that may improve memory is now being tested in a Phase 1 safety trial. The compound, BPN14770, was developed by Tetra Discovery Partners, with support from the NIH Blueprint Neurotherapeutics Network, a program designed to facilitate the discovery and development of novel neurological treatments. It is the first compound funded by the program to reach a Phase 1 clinical trial.

"We are pleased that BPN14770 has moved into a clinical study and we are eagerly awaiting the outcomes of the safety trial," said Amir Tamiz, Ph.D., program director at the NIH's National Institute of Neurological Disorders and Stroke (NINDS). The phase 1 study is being funded by the NINDS and the NIH's National Institute on Aging.

The compound is a first in class phosphodiesterase 4D negative allosteric modulator (PDE4D-NAM). PDE4D is an enzyme that plays a role in the formation of connections between brain cells. In addition, blocking PDE4D increases activity of cyclic adenosine monophosphate, a protein that enhances learning and memory. Rolipram is a different type of PDE4 inhibitor that has been shown to improve cognitive performance in mouse models of Alzheimer's disease, stroke and . Although rolipram has been effective in animal studies, it is not used clinically due to serious side effects. BPN14770 may be a possible treatment for dementia and Alzheimer's disease with less potential for side effects than rolipram.

The Phase 1 trial will test the safety and pharmacokinetics (what happens to the drug inside the body) of the compound in 48 healthy volunteers. If deemed safe, the next phase of testing will examine its effects on long-term memory and other aspects of cognition.

The NIH Blueprint Neurotherapeutics Network is a unique program that matches research scientists with drug discovery and development consultants and contract research organizations to speed up the rate at which potential drugs discovered in the lab move into clinical trials. Many principal investigators may not have the experience or resources to turn a newly discovered compound into a therapy. The Blueprint Neurotherapeutics Network grants them access to drug discovery experts who can guide them during the discovery and development stages.

"The goal of the Blueprint Neurotherapuetics Network is to rapidly move promising ideas for treating seemingly incurable neurological disorders from the lab bench to the bedside. The Network achieves this goal through collaborations between researchers, consultants and contractors. The consultants and contractors in the Neurotherapeutics Network provide their expertise to help investigators, many of whom may be new to drug development," said Dr. Tamiz.

Future research studies may test the effects of the in Alzheimer's patients as well as those with .

Explore further: New technique generates human neural stem cells for tissue engineering, 3-D brain models

Related Stories

Study reveals a biological link between stress and obesity

September 21, 2016

Metabolic and anxiety-related disorders both pose a significant healthcare burden, and are in the spotlight of contemporary research and therapeutic efforts. Although intuitively we assume that these two phenomena overlap, ...

Researchers working to advance aging research

August 17, 2016

Mayo Clinic, along with other members of the Geroscience Network, has published six manuscripts that map strategies for taking new drugs that target processes underlying aging into clinical trials. Researchers believe that ...

Recommended for you

Alzheimer's stemmed but not stopped, say experts

September 19, 2016

Soaring rates of population growth and ageing have long been seen as portending a global explosion of Alzheimer's, the debilitating disease that robs older people of their memory and independence.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

EnricM
not rated yet Jan 02, 2016
Would it be effective in healthy subjects?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.